9.1 C
New York
Friday, April 19, 2024

Cowen & Company Initiates Heron Therapeutics With Outperform

Courtesy of Benzinga.

Related
Heron Therapeutics Initiates Phase 2 Clinical Trial of HTX-011 for the Treatment of Post-Operative Pain
Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock, 5.520M Shares
5 Stocks Leading XBI Biotech ETF Higher (Seeking Alpha)

Analysts at Cowen & Company initiated coverage on Heron Therapeutics Inc (NASDAQ: HRTX) with a Outperform rating.

The target price for Heron Therapeutics is set to $40.

Heron Therapeutics’ shares rose 3.33 percent to $30.37 in pre-market trading.

Latest Ratings for HRTX

Date Firm Action From To
Jun 2015 Cowen & Company Initiates Coverage on Outperform
Jun 2015 Leerink Swann Maintains Outperform
Jun 2015 Leerink Swann Maintains Outperform

View More Analyst Ratings for HRTX
View the Latest Analyst Ratings

Posted-In: Cowen & CompanyInitiation Analyst Ratings

1 COMMENT

Subscribe
Notify of
1 Comment
Inline Feedbacks
View all comments

Stay Connected

157,350FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

1
0
Would love your thoughts, please comment.x
()
x